118 related articles for article (PubMed ID: 3468564)
21. Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6).
Pressacco J; Muller R; Kalow W
Eur J Clin Pharmacol; 1993; 45(3):261-4. PubMed ID: 8276051
[TBL] [Abstract][Full Text] [Related]
22. Lack association between schizophrenia and the CYP2D6 gene polymorphisms.
Pirmohamed M; Wild MJ; Kitteringham NR; O'Brien K; Buchan IE; Back DJ; Park BK
Am J Med Genet; 1996 Apr; 67(2):236-7. PubMed ID: 8723057
[No Abstract] [Full Text] [Related]
23. [The excessive activity of cytochrome P450 system in ALS--the metabolic ratio of sparteine].
Kaneko K; Atsumi T; Miyataka T
Rinsho Shinkeigaku; 1989 Oct; 29(10):1251-5. PubMed ID: 2605831
[TBL] [Abstract][Full Text] [Related]
24. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Fromm MF; Hofmann U; Griese EU; Mikus G
Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
[TBL] [Abstract][Full Text] [Related]
25. [Cytochrome p450 IID6, its role in psychopharmacology].
Lamard L; Pérault MC; Bouquet S; Guibert S
Ann Med Psychol (Paris); 1995 Feb; 153(2):140-3. PubMed ID: 7741408
[TBL] [Abstract][Full Text] [Related]
26. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
27. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
[TBL] [Abstract][Full Text] [Related]
28. Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis.
Jorge LF; Arias TD; Griese U; Nebert DW; Eichelbaum M
Pharmacogenetics; 1993 Oct; 3(5):231-8. PubMed ID: 7904509
[TBL] [Abstract][Full Text] [Related]
29. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci.
Elexpuru-Camiruaga J; Buxton N; Kandula V; Dias PS; Campbell D; McIntosh J; Broome J; Jones P; Inskip A; Alldersea J
Cancer Res; 1995 Oct; 55(19):4237-9. PubMed ID: 7671227
[TBL] [Abstract][Full Text] [Related]
30. Clinically significant cytochrome P-450 drug interactions--a comment.
Ford NF; Sonnichsen DS
Pharmacotherapy; 1998; 18(4):890-1; discussion 892-3. PubMed ID: 9692671
[No Abstract] [Full Text] [Related]
31. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.
Lennard MS; Iyun AO; Jackson PR; Tucker GT; Woods HF
Pharmacogenetics; 1992 Apr; 2(2):89-92. PubMed ID: 1302046
[TBL] [Abstract][Full Text] [Related]
32. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
Bordet R; Broly F; Destée A; Libersa C
Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
[No Abstract] [Full Text] [Related]
33. A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbé Guaymí Amerindians: a case of genetic divergence with tentative phylogenetic time frame for the pathway.
Arias TD; Inaba T; Cooke RG; Jorge LF
Clin Pharmacol Ther; 1988 Sep; 44(3):343-52. PubMed ID: 3416554
[TBL] [Abstract][Full Text] [Related]
34. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.
Yokota H; Tamura S; Furuya H; Kimura S; Watanabe M; Kanazawa I; Kondo I; Gonzalez FJ
Pharmacogenetics; 1993 Oct; 3(5):256-63. PubMed ID: 8287064
[TBL] [Abstract][Full Text] [Related]
35. Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes.
Narimatsu S; Kariya S; Isozaki S; Ohmori S; Kitada M; Hosokawa S; Masubuchi Y; Suzuki T
Biochem Biophys Res Commun; 1993 Jun; 193(3):1262-8. PubMed ID: 8323546
[TBL] [Abstract][Full Text] [Related]
36. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.
Zhou-Pan XR; Sérée E; Zhou XJ; Placidi M; Maurel P; Barra Y; Rahmani R
Cancer Res; 1993 Nov; 53(21):5121-6. PubMed ID: 8221648
[TBL] [Abstract][Full Text] [Related]
37. Metabolism of trimipramine in vitro by human CYP2D6 isozyme.
Bolaji OO; Coutts RT; Baker GB
Res Commun Chem Pathol Pharmacol; 1993 Oct; 82(1):111-20. PubMed ID: 8272570
[TBL] [Abstract][Full Text] [Related]
38. Computer prediction and experimental validation of cytochrome P4502D6-dependent oxidation of GBR 12909.
de Groot MJ; Bijloo GJ; Hansen KT; Vermeulen NP
Drug Metab Dispos; 1995 Jun; 23(6):667-9. PubMed ID: 7587951
[No Abstract] [Full Text] [Related]
39. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.
Gram LF; Brøsen K
Br J Clin Pharmacol; 1993 Jun; 35(6):649-52. PubMed ID: 8329293
[TBL] [Abstract][Full Text] [Related]
40. [Clinical aspects of the polymorphism of oxidation phenotype].
Mrozikiewicz PM
Pol Tyg Lek; 1992 Jul 6-13; 47(27-28):608-10. PubMed ID: 1488339
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
